<DOC>
	<DOCNO>NCT00037011</DOCNO>
	<brief_summary>RATIONALE : Biological therapy beta-glucan use different way stimulate immune system stop cancer cell grow . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining beta-glucan monoclonal antibody may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine beta-glucan monoclonal antibody treat patient metastatic neuroblastoma .</brief_summary>
	<brief_title>Beta-Glucan Monoclonal Antibody Treating Patients With Metastatic Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose beta-glucan monoclonal antibody 3F8 patient metastatic neuroblastoma . - Determine toxicity regimen patient . - Assess biological effect regimen patient . OUTLINE : This dose-escalation study . Patients receive oral beta-glucan monoclonal antibody 3F8 ( MOAB 3F8 ) IV within 1.5 hour day 1-5 8-12 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos beta-glucan MOAB 3F8 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow monthly 6 month , every 2 month 6 month , every 3-6 month 2 year . PROJECTED ACCRUAL : A maximum 24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highrisk stage 4 metastatic neuroblastoma May confirm bone marrow involvement elevate urinary catecholamine Progressive persistent disease intensive conventional chemotherapy include induction N6 , N7 , N8 , COG protocol without bone marrow stem cell transplantation Poor longterm prognosis define follow : Nmyc amplification tumor cell Diploid chromosomal content plus 1p loss heterozygosity tumor cell Distant skeletal metastasis Unresectable primary tumor infiltrate across midline More 10 % tumor cell bone marrow Measurable evaluable disease document least 4 week completion prior systemic therapy PATIENT CHARACTERISTICS : Age : Under 50 Performance status : Not specify Life expectancy : See Disease Characteristics Hematopoietic : Platelet count great 25,000/mm^3 Absolute neutrophil count great 500/mm^3 Hepatic : Not specify Renal : Creatinine clearance great 60 mL/min Other : No severe major organ toxicity No active lifethreatening infection No prior allergy mouse proteins No prior allergy betaglucan , oat , barley , mushroom , yeast Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior exposure mouse antibody human antimouse antibody great 1,000 ELISA units/mL Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent supplemental betaglucan either food ( e.g. , bran cereal ) complementary medicine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>